Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly reports positive LY2140023 phase II study results

Eli Lilly reports positive LY2140023 phase II study results

3rd September 2007

Eli Lilly has announced positive phase II clinical trial results of its investigational compound LY2140023, with the drug displaying antipsychotic activity in patients.

The trial results, published in the Nature Medical journal, show administration of the drug results in a statistically significant improvement in the positive and negative syndrome scale when compared with placebo.

Furthermore, patients administered with LY2140023 did not exhibit specific adverse effects usually related to existing schizophrenia drugs, including extrapyramidal symptoms, prolactin elevations and weight gain.

LY2140023 is an oral prodrug that provides the active mGlu2/3 receptor agnonist LY404039 when metabolised and is thought to operate by the reduction of presynaptic release of the glutamate neurotransmitter in the region of the brain where mGlu2/3 receptors are expressed.

Steven Paul, executive vice-president of science and technology at Lilly, said: “These data provide compelling new evidence that mGlu2/3 receptor agonists have antipsychotic properties and may provide a completely new therapeutic approach for treating schizophrenia and perhaps other neuropsychiatric disorders.”

He added that further studies are needed to confirm these results, while the compound could provide an alternative treatment options for schizophrenia patients.

In April 2007, Lilly announced the publication of data suggesting that the assessment of response to treatment with antipsychotics in patients with schizophrenia could be made earlier than is currently believed, with early exhibition of non-response a possible robust predictor of later non-response.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.